Announcements Trials

Browse Landscape

Phase

Phase 2 10 Phase 3 6 Phase 1/2 5 Phase 1 4 Phase 2/3 1

Status

Sponsor Class

OTHER 4 NETWORK 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Glioblastoma 1 Astrocytoma 1

Interventions

Cisplatin 29 Carboplatin 28 Gemcitabine 27 Paclitaxel 26 pembrolizumab 24 Capecitabine 16 Pemetrexed 15 Bevacizumab 15 Docetaxel 14 Oxaliplatin 13 Fluorouracil 12 Drug Therapy 12 Nivolumab 10 130-nm albumin-bound paclitaxel 9 anlotinib 7 Trastuzumab 7 Injections 7 Rituximab 6 atezolizumab 5 Temozolomide 5 Leucovorin 5 Ipilimumab 5 venetoclax 4 Lenalidomide 4 Irinotecan 4 Interferon alpha-2 4 Folfox protocol 4 Dexamethasone 4 Albumin-Bound Paclitaxel 4 sintilimab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × INDUSTRY × Lomustine × Clear all

NCT02414165 2020-02-07

Toca5

Tocagen Inc.

Phase 2/3 Terminated

Astrocytoma, Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡